David A. Ostrowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David A. Ostrowski has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Daniel J. Lee
Division of Urology, University of Pennsylvania, Philadelphia, PA
2 shared publications Alan J. Wein
Division of Urology, Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA, USA
1 shared publication- Ariana L. Smith
Division of Urology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
1 shared publication Brian D. Cortese
Division of Urology, Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA, USA
1 shared publication- Brian D. Cortese
Department of Urology, Vanderbilt University Medical Center, Nashville, TN
1 shared publication Christopher J. Long
Division of Urology, Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
1 shared publication
Latest Publications
- Open Access
Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer
The ongoing Bacillus Calmette-Guérin (BCG) shortage has created challenges for the treatment of non-muscle invasive bladder cancer (NMIBCa). Our objective was to evaluate the efficacy of reduced-dose induction BCG (RD-iBCG) compared to full-dose induction BCG (FD-iBCG) regarding recurrence rates. We hypothesized that patients receiving RD-iBCG may recur at a higher rate compared to those who received FD-iBCG therapy. A retrospective review of all patients with NMIBCa treated with intravesical therapy at our institution between 2015–2020 was conducted. Inclusion criteria consisted of having a diagnosis of AUA intermediate or high-risk NMIBCa with an indication for a six-week induction course of FD or RD-BCG with at least 1 year of documented follow up. The data were censored at one year. Propensity score matching for age, sex, tumor pathology, and initial vs. recurrent disease was performed. The primary endpoint was bladder cancer recurrence, reported as recurrence-free survival. A total of 254 patients were reviewed for this study. Our final cohort was 139 patients after exclusion. Thirty-nine percent of patients had HGT1 disease. 38.6% of patients receiving RD-BCG developed a recurrence of bladder cancer within a one-year follow-up as compared to 33.7% of patients receiving FD therapy. After propensity matching, this value remained statistically significant (p = 0.03). In conclusion, RD-iBCG for NMIBCa is associated with a significantly greater risk of recurrence than full-dose induction therapy, suggesting that RD-iBCG may not be equivalent or non-inferior to full-dose administration in the short term.
Open AccessDiminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer
The ongoing Bacillus Calmette-Guérin (BCG) shortage has created challenges for the treatment of non-muscle invasive bladder cancer (NMIBCa). Our objective was to evaluate the efficacy of reduced-dose induction BCG (RD-iBCG) compared to full-dose induction BCG (FD-iBCG) regarding recurrence rates. We hypothesized that patients receiving RD-iBCG may recur at a higher rate compared to those who received FD-iBCG therapy. A retrospective review of all patients with NMIBCa treated with intravesical therapy at our institution between 2015–2020 was conducted. Inclusion criteria consisted of having a diagnosis of AUA intermediate or high-risk NMIBCa with an indication for a six-week induction course of FD or RD-BCG with at least 1 year of documented follow up. The data were censored at one year. Propensity score matching for age, sex, tumor pathology, and initial vs. recurrent disease was performed. The primary endpoint was bladder cancer recurrence, reported as recurrence-free survival. A total of 254 patients were reviewed for this study. Our final cohort was 139 patients after exclusion. Thirty-nine percent of patients had HGT1 disease. 38.6% of patients receiving RD-BCG developed a recurrence of bladder cancer within a one-year follow-up as compared to 33.7% of patients receiving FD therapy. After propensity matching, this value remained statistically significant (p = 0.03). In conclusion, RD-iBCG for NMIBCa is associated with a significantly greater risk of recurrence than full-dose induction therapy, suggesting that RD-iBCG may not be equivalent or non-inferior to full-dose administration in the short term.
- 26 May 2023
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 19 (5) , 566.e1-566.e8
Automated Society of Fetal Urology (SFU) grading of hydronephrosis on ultrasound imaging using a convolutional neural network
- 26 May 2023
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 19 (5) , 566.e1-566.e8
Automated Society of Fetal Urology (SFU) grading of hydronephrosis on ultrasound imaging using a convolutional neural network
- Open Access
- 19 July 2022
- Published by Elsevier in Urology Case Reports
- Vol. 44, 102165
Spontaneous rupture of a bladder diverticulum with delayed open surgical repair
- 19 July 2022
- Published by Elsevier in Urology Case Reports
- Vol. 44, 102165
Open AccessSpontaneous rupture of a bladder diverticulum with delayed open surgical repair